Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised multicentre open adaptive multi-arm multi-stage trial

Catalyst investigators, Pamela Kearns, Tonny Veenith et al.|Unknown|2021

Cited by 0